National Brain Tumor Society’s DNA Damage Response (DDR) Consortium is a collaboration of world-class researchers advancing an emerging and promising, but underdeveloped, area of cancer research: a tumor’s DDR network. To bring forth a concerted effort to advance this strategy, NBTS has formed a consortium of leading experts in both pediatric and adult neuro-oncology research to go “all-in” in pursuit of making the promise of this approach a reality for patients.
The consortium will test different drugs in the laboratory, share data, and then bring the most promising drugs forward to evaluate in clinical trials that match the right drugs with the right patients. The consortium is made up of a diverse team of world-class researchers from across the United States with unparalleled expertise and the experience needed to rapidly develop and advance these drugs into clinical trials.
As a result of your generous support, this includes an ependymoma research effort led by the team at St. Jude Children’s Research Hospital within the DNA Damage Response Consortium.